Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)
September 03, 2024 02:30 ET
|
Ultragenyx Pharmaceutical Inc.
MADRID, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), una empresa biofarmacéutica centrada en el desarrollo y la comercialización de nuevos tratamientos para...
Ultragenyx to Participate in Investor Conferences in September
August 29, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
Morgan Stanley 22nd Annual Global Healthcare Conference on September 4 Cantor Global Healthcare Conference on September 17 Bank of America Global Healthcare Conference on September 18 NOVATO,...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
August 21, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Reports Second Quarter 2024 Financial Results and Corporate Update
August 01, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Second quarter total revenue of $147 million, Crysvita® revenue of $114 million and Dojolvi® revenue of $19 million Increased 2024 expected total revenue guidance to $530 million to $550 million ...
Ultragenyx to Host Conference Call for Second Quarter 2024 Financial Results and Corporate Update
July 25, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for...
Ultragenyx to Present GTX-102 Angelman Syndrome Program Update at the ASF Family Conference and Research Symposium
July 24, 2024 08:00 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that the company will share the latest clinical data, regulatory progress and program...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
July 19, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., July 19, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102 Angelman Syndrome Program
July 17, 2024 16:05 ET
|
Ultragenyx Pharmaceutical Inc.
Alignment with FDA on Phase 3 study primary endpoint of Bayley-4 cognition and key secondary endpoint of Multi-Domain Responder Index (MDRI) Phase 3 study on track to initiate by the end of this...
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2024 16:30 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...
Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
June 13, 2024 20:49 ET
|
Ultragenyx Pharmaceutical Inc.
NOVATO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for...